Macrocyclics

Biotechnology ResearchTexas, United States11-50 Employees

Macrocyclics, Inc. operates in the biotechnology research industry and manufactures customized chelating agents, with a focus on developing chelation chemistry platforms for diagnostic and therapeutic medicine. The company provides a broad library of catalog products and also offers custom cGMP products and services to support early-stage clinical development, along with expert consulting in chelation chemistry and bioconjugation. Macrocyclics' molecular imaging platform is adaptable to radionuclides for positron emission tomography, including copper-64, gallium-68, and zirconium-89, as well as gadolinium and other lanthanide ions for optical and magnetic resonance imaging. Its product line includes bifunctional ligands designed for bio-targeting in combination with monoclonal antibodies and peptide fragments, and the company has operated since 1996. The company is based at 700 Klein Road, Plano, Texas 75074, United States, employs 11-50 people, and has a history of corporate activity including a 2011 acquisition by Orano Med SAS and a 2025 exclusive manufacturing and distribution partnership with Ratio Therapeutics.

Sign up for free to view info

Email Format Employee directory